Zilver stent versus Carotid Wallstent for endovascular treatment of idiopathic intracranial hypertension

被引:6
|
作者
Bilgin, Cem [1 ,7 ]
Oliver, Alexander A. [2 ]
Cutsforth-Gregory, Jeremy K. [3 ]
Chen, John J. [4 ]
Rammos, Stylianos K. [5 ]
Cloft, Harry J. [1 ]
Lanzino, Giuseppe [6 ]
Kallmes, David F. [1 ]
Brinjikji, Waleed [1 ]
机构
[1] Mayo Clin, Radiol, Rochester, MN 55905 USA
[2] Mayo Clin Minnesota, Biomed Engn, Rochester, MN USA
[3] Mayo Clin, Neurol, Rochester, MN 55905 USA
[4] Mayo Clin, Ophthalmol, Rochester, MN 55905 USA
[5] Arkansas Neurosci Inst, Neurosurg, Little Rock, AR USA
[6] Mayo Clin Minnesota, Neurosurg, Rochester, MN USA
[7] Mayo Clin, Dept Radiol, Rochester, MN 55905 USA
基金
美国国家卫生研究院;
关键词
Intracranial Pressure; Stenosis; Stent; SINUS; PRESSURE; STENOSIS;
D O I
10.1136/jnis-2022-019659
中图分类号
R445 [影像诊断学];
学科分类号
100207 ;
摘要
BackgroundVenous sinus stenting (VSS) is a promising treatment option for medically refractory idiopathic intracranial hypertension (IIH). There are no published studies comparing the performance of different types of stents employed in VSS procedures. In this study we aimed to compare the safety and efficacy outcomes of the Zilver 518 (Cook Medical, Bloomington, Indiana, USA) and the Carotid Wallstent (Boston Scientific, Marlborough, Massachusetts, USA) devices. MethodsRecords of patients with IIH who underwent VSS between January 2015 and February 2022 at a single referral center were retrospectively reviewed. Patients treated with the Zilver stent or Carotid Wallstent were included in the study. Stent model and size data, pre- and post-treatment pressure gradients, technical and safety outcomes, and pre- and post- stenting papilledema, headache, and tinnitus severity were collected. The chi(2) and Fisher-Freeman-Halton tests were used for categorical data and the Student's t-test and Mann-Whitney U test were employed to examine the differences in non-categorical variables. ResultsA total of 81 procedures (28 (34.5%) with the Zilver stent and 53 (65.5%) with the Carotid Wallstent) were performed in 76 patients. The mean procedure time was significantly shorter with the Zilver stent (22.56 +/- 10.2 vs 33.9 +/- 15 min, p=0.001). The papilledema improvement and resolution rates did not significantly differ between groups (94.7% vs 94.5%, p>0.99 for improvement; 78.9% vs 67.5%, p=0.37 for resolution). The tinnitus improvement and resolution rates in the Zilver stent group were significantly higher than those of the Carotid Wallstent group (100% vs 78.9%, p=0.041; 90% vs 63.1%, p=0.03, respectively). Additionally, the Zilver stent provided a significantly higher rate of headache resolution and improvement than the Carotid Wallstent (84.6% vs 27.6%, p=0.001 for resolution; 92.3% vs 72.3%, p=0.043 for improvement). One patient from the Carotid Wallstent group underwent re-stenting due to in-stent stenosis and refractory papilledema. No significant in-stent stenosis was observed in the Zilver stent group. ConclusionStent choice may affect VSS outcomes. The Zilver stent provided better clinical outcomes than the Carotid Wallstent, with significantly shorter procedure times. Larger studies are needed to determine the efficacy of available venous stents for IIH.
引用
收藏
页码:1269 / +
页数:6
相关论文
共 50 条
  • [21] Efficacy of endovascular stenting in dural venous sinus stenosis for the treatment of idiopathic intracranial hypertension
    Arac, Ahmet
    Lee, Marco
    Steinberg, Gary K.
    Marcellus, Mary
    Marks, Michael P.
    NEUROSURGICAL FOCUS, 2009, 27 (05) : E14.1 - E14.8
  • [22] Endovascular treatment of idiopathic intracranial hypertension - Clinical and radiologic outcome of 10 consecutive patients
    Donnet, A.
    Metellus, P.
    Levrier, O.
    Mekkaoui, C.
    Fuentes, S.
    Dufour, H.
    Conrath, J.
    Grisoli, F.
    NEUROLOGY, 2008, 70 (08) : 641 - 647
  • [23] Diagnosis and treatment of idiopathic intracranial hypertension
    Raoof, Naz
    Hoffmann, Jan
    CEPHALALGIA, 2021, 41 (04) : 472 - 478
  • [24] Idiopathic Intracranial Hypertension pathogenesis and treatment
    Eftekhari, Sajedeh
    ACTA PHYSIOLOGICA, 2019, 227 : 42 - 42
  • [25] TREATMENT OF IDIOPATHIC INTRACRANIAL HYPERTENSION WITH DIGOXIN
    GOODWIN, JA
    ANNALS OF NEUROLOGY, 1990, 28 (02) : 248 - 248
  • [26] Idiopathic Intracranial Hypertension Treatment Trial
    Wall, Michael
    Kupersmith, Mark
    Corbett, James
    Kieburtz, Karl
    McDermott, Michael
    Friedman, Deborah
    Feldon, Steven
    Keltner, John
    NEUROLOGY, 2010, 74 (09) : A540 - A540
  • [27] Acetazolamide for the treatment of idiopathic intracranial hypertension
    Supuran, Claudiu T.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2015, 15 (08) : 851 - 856
  • [28] Endovascular Stenting of Venous Sinus Stenosis for Idiopathic Intracranial Hypertension
    Pandey, Paritosh
    Steinberg, Gary K.
    WORLD NEUROSURGERY, 2011, 75 (5-6) : 594 - 595
  • [29] Endovascular stenting for idiopathic intracranial hypertension with venous sinus stenosis
    Liu, Xinfeng
    Di, Hai
    Wang, Jun
    Cao, Xiangyu
    Du, Zhihua
    Zhang, Rongju
    Yu, Shengyuan
    Li, Baomin
    BRAIN AND BEHAVIOR, 2019, 9 (05):
  • [30] Endovascular treatment of intracranial atherosclerotic stenoses with the Enterprise stent
    Schmid, E.
    Vajda, Z.
    Kloetzsch, C.
    Niehaus, L.
    Lindner, A.
    Peters, J.
    Baezner, H.
    Henkes, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 26 - 26